China health innovation ecosystem

A Cancerappy delegation has participated in a roadshow of European companies to learn about the innovative health ecosystem in the Shanghai and Wuxi area. Our CEO has had the opportunity to hold various meetings with different agents of the innovation ecosystem,...

CancerAppy Contributes to Innovative Scientific Paper on ADCs in Clinical Use

CancerAppy pioneers in ADC research, contributing to a transformative scientific paper. Our team's dedication unveils insights on payload properties, shaping the future of ADC therapies. A crucial leap in cancer treatment. We are proud to announce our significant...

CancerAppy at ESMO Congress: Pioneering Research Unveiled!

CancerAppy's groundbreaking study at ESMO Congress (Oct '23) reveals profound insights into Treg impact on tumor immune responses. Unearthing common transcripts and potential predictors, our AI-driven research shapes the future of cancer treatment.CancerAppy has...

Milestone Achieved: CancerAppy’s First Collaborative Research Paper Unveiled

We are delighted to announce our first collaborative scientific research article. At CancerAppy, our commitment to harnessing the power of AI in cancer drug discovery has led us to join forces with leading researchers in the field. This groundbreaking collaboration...

BIO Spain

We're excited to be part of BioSpain 2023, and despite our packed schedule, we welcome you to connect with us at the BasqueHealthCluster booth. Explore our groundbreaking work in the world of biotechnology and cancer research. See you there!. More about BIO Spain

ATG symbio Spain

Cancerappy participated in the II international congress organized by ATG Symbio Spain that was held inBarcelona at the Biomedical Research Park (PRBB) on July 1 and 2, 2023.Our CEO had the opportunity to present our company and show our latest advances in the NMEs...

Bio International Convention – Boston 23

Our CEO will be attending the BIO International in Boston from June 5th to 8th. Cancerappy is dedicated to the discovery and development of new AI-based pharmaceuticals. Currently, we have a strong pipeline that validates and demonstrates our value proposition. If you...

HONG KONG INVEST – European Companies Roadshow

From 15th to 18th of May, our CEO and CMO will be attending various international events in Hong Kong introducing the latest advances of our company. They will attend Asia Summit on Global Health, Invest in Honk Kong #investHK, and different meeting with local...


Our CEO Luis Martín Ezama will be attending the #Meet2win23 event 11th and 12th of May, exposing the characteristics of our pipeline of new cancer drugs. We are developing first-in-class antibodies and small molecules against solid tumors.



CA05 Lead Identification

We have identified insilico, several compounds as inhibitors of CA05, which is a protein kinase overexpressed in various types of tumors with a clear oncogenic role and no type-specific inhibitor, and we have started in vitro trials to select a lead.

CA02/03 Target Identification vs NSCLC

CancerAppy has identified two membrane proteins that are upregulated in NSCLC and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies


4YFN 2021

Cancerappy has been selected to participate in the Espacio España 4YFN 2021.